Orphazyme A/S (OZYMF)
USD 90.0
(0.0%)
USD 90.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 27.04 Thousand DKK | -33.16% |
| 2022 | 40.45 Million USD | 305.01% |
| 2021 | 9.98 Million DKK | -89.93% |
| 2020 | 99.17 Million DKK | 98.77% |
| 2019 | 49.89 Million DKK | -78.33% |
| 2018 | 230.28 Million DKK | 76.74% |
| 2017 | 130.29 Million DKK | 107.43% |
| 2016 | 62.81 Million DKK | 18.33% |
| 2015 | 53.08 Million DKK | 43.09% |
| 2014 | 37.09 Million DKK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 213.8 Thousand USD | 0.0% |
| 2023 FY | 27.04 Million DKK | -33.16% |
| 2023 Q2 | 1.87 Million USD | 0.0% |
| 2023 Q4 | 2.1 Million USD | 0.0% |
| 2022 FY | 40.45 Million USD | 305.01% |
| 2022 Q4 | 1.73 Million USD | 0.0% |
| 2022 Q2 | 3.83 Million USD | 0.0% |
| 2021 FY | 9.98 Million DKK | -89.93% |
| 2020 FY | 99.17 Million DKK | 98.77% |
| 2019 FY | 49.89 Million DKK | -78.33% |
| 2018 FY | 230.28 Million DKK | 76.74% |
| 2017 FY | 130.29 Million DKK | 107.43% |
| 2016 FY | 62.81 Million DKK | 18.33% |
| 2015 FY | 53.08 Million DKK | 43.09% |
| 2014 FY | 37.09 Million DKK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 99.969% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 99.45% |
| SQZ Biotechnologies Company | 85.61 Million USD | 99.968% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 99.908% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 99.927% |
| Mesoblast Limited | 5.9 Million USD | 99.542% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 98.2% |
| Genus plc | 147.7 Million USD | 99.982% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 99.692% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 97.984% |
| Marizyme, Inc. | 19.23 Million USD | 99.859% |
| ContraFect Corporation | 56.88 Million USD | 99.952% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 99.676% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 99.387% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 98.171% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 99.073% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 99.031% |
| MultiCell Technologies, Inc. | 567.42 USD | -4665.606% |
| Accustem Sciences Inc. | 3.74 Million USD | 99.278% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 99.969% |
| EV Biologics, Inc. | 531.96 Thousand USD | 94.917% |
| Q BioMed Inc. | 3.43 Million USD | 99.213% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 99.891% |
| Neon Bloom, Inc. | 389.56 Thousand USD | 93.059% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 98.971% |
| Biomind Labs Inc. | 994.18 Thousand USD | 97.28% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 99.988% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 99.597% |
| Skye Bioscience, Inc. | 13.54 Million USD | 99.8% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 98.68% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 208.164% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 99.464% |
| IMV Inc. | 37.7 Million USD | 99.928% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 99.831% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 98.526% |
| GB Sciences, Inc. | 1.42 Million USD | 98.096% |
| Alpha Cognition Inc. | 9.7 Million USD | 99.721% |
| HST Global, Inc. | 140.9 Thousand USD | 80.809% |
| CSL Limited | 3.44 Billion USD | 99.999% |
| Halberd Corporation | 74.84 Thousand USD | 63.869% |
| Enzolytics Inc. | 2.17 Million USD | 98.759% |
| Resverlogix Corp. | 12.71 Million USD | 99.787% |
| Affymax, Inc. | 39.38 Million USD | 99.931% |
| SYBLEU INC | 160.87 Thousand USD | 83.191% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 99.259% |
| argenx SE | 1.53 Billion USD | 99.998% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 99.953% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 97.41% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 98.288% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 99.206% |
| AVAX Technologies, Inc. | 7.31 Million USD | 99.63% |
| Zenith Capital Corp. | 8.94 Million USD | 99.698% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.997% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -55.221% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 98.899% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | 84.233% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.973% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 98.463% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 1.97 Million USD | 98.629% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 98.55% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 99.751% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 98.592% |
| BioStem Technologies, Inc. | 22.97 Million USD | 99.882% |
| ONE Bio Corp. | 6.44 Million USD | 99.58% |
| Reve Technologies, Inc. | 181.48 Thousand USD | 85.1% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | 97.975% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 97.596% |
| Agentix Corp. | 1.37 Million USD | 98.029% |
| LadRx Corporation | 3.81 Million USD | 99.291% |
| Cell Source, Inc. | 4.32 Million USD | 99.375% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | 93.492% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 97.072% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 97.072% |
| NovAccess Global Inc. | 2.46 Million USD | 98.904% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 98.876% |
| Itoco Inc. | 919.14 Thousand USD | 97.058% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 99.362% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 97.583% |
| Kadimastem Ltd | 2.41 Million USD | 98.878% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | 89.668% |
| CytoDyn Inc. | 18.05 Million USD | 99.85% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -7.438% |
| Mobile Lads Corp. | 554.54 Thousand USD | 95.124% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | 87.713% |
| Qrons Inc. | 643.67 Thousand USD | 95.799% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 98.095% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | 98.787% |
| Rebus Holdings, Inc. | 664 Thousand USD | 95.928% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 98.511% |
| International Stem Cell Corporation | 5.27 Million USD | 99.487% |
| Bioxytran, Inc. | 3.82 Million USD | 99.292% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | 48.632% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -32.925% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 99.925% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 98.329% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | 96.325% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 99.131% |
| Neutra Corp. | 243.82 Thousand USD | 88.909% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 99.845% |
| PureTech Health plc | 144.59 Million USD | 99.981% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 99.868% |
| IXICO plc | 4.7 Million USD | 99.426% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 99.693% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.977% |
| CSL Limited | 3.89 Billion USD | 99.999% |
| Cellectis S.A. | 97.32 Million USD | 99.972% |